Patents by Inventor Marie Annick Buendia

Marie Annick Buendia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen
    Patent number: 9347088
    Abstract: The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of the liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in a sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: May 24, 2016
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Marie-Annick Buendia, Carolina Armengol Niell, Stefano Cairo, Aurélien de Reynies
  • MOLECULAR SIGNATURE OF LIVER TUMOR GRADE AND USE TO EVALUATE PROGNOSIS AND THERAPEUTIC REGIMEN
    Publication number: 20120040848
    Abstract: The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient.
    Type: Application
    Filed: June 26, 2009
    Publication date: February 16, 2012
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Marie-Annick Buendia, Carolina Niell, Stefano Cairo, Aurelien de Reynies
  • MOLECULAR SIGNATURE OF LIVER TUMOR GRADE AND USE TO EVALUATE PROGNOSIS AND THERAPEUTIC REGIMEN
    Publication number: 20110183862
    Abstract: The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of the liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in a sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient.
    Type: Application
    Filed: June 26, 2009
    Publication date: July 28, 2011
    Inventors: Marie Annick Buendia, Carolina Armengol Niell, Stefano Cairo, Aurélien de Reynies
  • Diagnostic means useful for predictive assessment of human hepatocellular carcinoma disease (HCC), as well as diagnostic methods using the same
    Publication number: 20040076950
    Abstract: Compositions for the diagnosis of hepatocellular carcinoma (HCC), tumor suppressor genes associated with HCC, methods for diagnosing various forms of HCC, methods for detecting genetic abnormalities associated with HCC, as well as kits for carrying out the methods, are disclosed.
    Type: Application
    Filed: March 28, 2001
    Publication date: April 22, 2004
    Applicants: Institut Pasteur, Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Anne Dejean, Marie Annick Buendia, Pascal Pineau, Hisaki Nagai
  • Diagnostic means useful for predictive assessment of human hepatocellular carcinoma disease (HCC), as well as diagnostic methods using the same
    Patent number: 6410724
    Abstract: The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: June 25, 2002
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Anne Dejean, Marie-Annick Buendia, Pascal Pineau, Hisaki Nagai, Pierre Tiollais
  • Diagnostic means useful for predictive assessment of human hepatocellular carcinoma disease (HCC), as well as diagnostic methods using the same
    Publication number: 20020042073
    Abstract: The present invention pertains to new polynucleotides or new combinations of polynucleotides useful as diagnostic tools for predicting the occurrence of a human hepatocellular carcinoma disease. The invention is also directed to polynucleotides that consist in candidate tumor suppressor genes the alteration of which is involved in the occurrence of hepatocellular carcinoma in a patient, as well as to polynucleotides derived from such new candidate tumor suppressor genes and to the corresponding expressed polypeptides. The invention also concerns diagnostic methods using said polynucleotides as diagnostic tools.
    Type: Application
    Filed: July 6, 2001
    Publication date: April 11, 2002
    Applicant: INSTITUT PASTEUR
    Inventors: Anne Dejean, Marie-Annick Buendia, Pascal Pineau, Hisaki Nagai, Pierre Tiollais
  • Diagnostic means useful for predictive assessment of human hepatocellular carcinoma disease (HCC), as well as diagnostic methods using the same
    Patent number: 6265161
    Abstract: A method for detecting a predisposition to hepatocellular carcinoma (HCC) using a unique panel of primers for identifying genetic alterations that are linked to HCC, as well as kits for carrying out the methods, are disclosed.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: July 24, 2001
    Assignee: Institut Pasteur and Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Anne Dejean, Marie Annick Buendia, Pascal Pineau, Hisaki Nagai